A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?

Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Publication: [Philadelphia, PA] : Taylor & Francis
Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989-

Peripheral Nervous System Diseases*/chemically induced ; Peripheral Nervous System Diseases*/epidemiology ; Peripheral Nervous System Diseases*/diagnosis ; Cyclophosphamide*/adverse effects ; Cyclophosphamide*/therapeutic use ; Lymphoma, Non-Hodgkin*/drug therapy ; Lymphoma, Non-Hodgkin*/epidemiology ; Lymphoma, Non-Hodgkin*/complications ; Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Vincristine*/adverse effects ; Vincristine*/therapeutic use ; Rituximab*/adverse effects ; Rituximab*/administration & dosage ; Doxorubicin*/adverse effects ; Doxorubicin*/therapeutic use ; Prednisone*/adverse effects ; Prednisone*/therapeutic use ; HIV Infections*/drug therapy ; HIV Infections*/complications ; Etoposide*/adverse effects ; Etoposide*/administration & dosage ; Etoposide*/therapeutic use; Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Aged ; Incidence

The frontline immuno-chemotherapy regimen for HIV-associated non-Hodgkin Lymphoma is dose-adjusted EPOCH ± R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab). Chemotherapy-induced peripheral neuropathy (CIPN), caused by vincristine, is a common adverse effect of EPOCH ± R, negatively impacting long-term patient outcomes. The primary objective of this study was to determine the incidence of CIPN, stratified by HIV status, in patients treated with EPOCH ± R. A retrospective cohort study at a tertiary referral comprehensive cancer center evaluated patients treated with EPOCH ± R from 2011 to 2018. The final sample included 27 patients with HIV compared to 279 without HIV (total n  = 306). Overall, the incidence of CIPN was 29.4% ( n  = 90), including 5 with HIV (18.5%) and 85 without HIV (30.5%). Propensity scores were used to match patients by HIV status. Although no relationship was found between HIV status and neuropathy, CIPN affects too many undergoing treatments for lymphoma, supporting future investigations to minimize toxicities.

Keywords: Chemotherapy-induced peripheral neuropathy; EPOCH ± R; HIV; lymphoma; vincristine

8N3DW7272P (Cyclophosphamide)
5J49Q6B70F (Vincristine)
4F4X42SYQ6 (Rituximab)
80168379AG (Doxorubicin)
VB0R961HZT (Prednisone)
6PLQ3CP4P3 (Etoposide)

EPOCH protocol

Date Created: 20240422 Date Completed: 20240723 Latest Revision: 20240822

20240822

10.1080/10428194.2024.2340051

38648546